CSL and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare has granted approval for ...

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 ...

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

Bucillamine (N- (mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years.

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® ...

Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Australian biotechnology company CSL Ltd. (CSL.AX, CSLLY.PK) and sa-mRNA pioneer Arcturus Therapeutics (ARCT), announced Friday that ...

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious ...

King of Prussia, Pennsylvania Monday, September 16, 2024, 17:00 Hrs [IST] ...